|Pipeline||Discovery||Pre-clinical Studies||Phase Ⅰ Studies||Phase Ⅱ Studies||Phase Ⅲ Studies||NDA / BLA||Market|
TMB-370 is the third generation recombinant monoclonal antibody in TaiMed Biologics, and newly developed and licensed from Aaron Diamond AIDS Research Center (ADARC). TMB-370 is a genuine bispecific neutralizing antibody whose unique structure shares a common immunoglobin Y-shape structure, with biological activity of targeting two different antigens against HIV infections, one targeting human CD4 receptor like TMB-355 (ibalizumab, IBA), the other targeting HIV envelop protein gp41 like 10E8. The characteristics of broad coverage and long-lasting of TMB-370 are within a single compound which is referred by modern medication trend. TMB-370 shares great advantages not only on the CMC (Chemical, Manufacture, Control) but also the safety and efficacy thru the unique characteristics from the compound per se.
Schematic of TMB-370, 10E8.4/iMab.
TMB-370 is focused upon treatment against HIV infections.
With regards to the biological activity against cross-clades viruses in vitro, TMB-370 is superior in comparison to the mixture of the dedicated neutralizing antibodies as well as individual designated neutralizing antibodies where TMB-370 is derived.
Impressive breadth and potency against HIV of the engineered TMB-370 10E8.4/iMab
With regards to therapeutic efficacy against cross-clades viruses in vivo, TMB-370 is supreme performer in comparison to the mixture of the dedicated neutralizing antibodies as well as individual designated neutralizing antibodies where TMB-370 is derived.
Eminent therapeutic efficacy of TMB-370 10E8.4/iMab in virus-challenged humanized mice
Huang Y., et al. Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity. Cell 2016, 165; 1621.
Padte N., et al. Engineering multi-specific antibodies against HIV-1. Retrovirology 2018, 15; 60.